MRinRT 2024

Start Date: Apr 3rd, 2024 09:58

End Date: Apr 5th, 2024 09:17

URL: http://www.mrinrt2024.com

Location: Rome, Italy

MRinRT 2024 Scientific Rationale

 

• Introduction to Precision MR guided Radiotherapy: The congress aims to explore the latest developments in utilizing Magnetic Resonance Imaging (MRI) for enhancing precision in radiotherapy, a critical component in cancer treatment.

 

• Improved Soft Tissue Visualization: MRI provides superior soft tissue contrast compared to traditional imaging modalities, allowing for more accurate delineation of tumors and surrounding healthy tissues, ultimately leading to improved target delineation and treatment planning.

 

• Real-Time Imaging and Adaptive Planning: The integration of MRI into radiotherapy enables real-time imaging during treatment sessions, allowing for dynamic adaptation of treatment plans based on anatomical changes, enhancing treatment accuracy and reducing the risk of damage to adjacent healthy tissues.

 

• Functional Imaging for Treatment Response Assessment: Advanced MRI techniques such as diffusion-weighted imaging and functional MRI offer insights into tumor microenvironments and can be used for early assessment of treatment response, facilitating timely modifications to the treatment strategy.

 

• Motion Management and Target Tracking: With its ability to capture dynamic changes in anatomy, MRI aids in addressing challenges related to respiratory and organ motion, contributing to the development of effective strategies for target tracking and management.

 

• Enhancing Radiotherapy Guidance: The integration of MRI with radiotherapy devices improves image-guided radiation therapy (IGRT), enabling precise alignment of the treatment beam with the target volume, minimizing irradiation of surrounding healthy tissues.

 

• Potential for Reduced Margins and Dose Escalation: Accurate tumor delineation provided by MRI allows for the exploration of reduced treatment margins, potentially minimizing unnecessary exposure to healthy tissues. Additionally, MRI-guided dose escalation studies will be discussed for maximizing therapeutic benefits.

 

• Radiomics and Machine Learning Integration: The congress will delve into the application of radiomics and machine learning techniques in analyzing vast datasets generated by MRI, aiming to identify imaging biomarkers for predicting treatment outcomes and personalizing radiotherapy plans.

 

• Clinical Impact and Patient Outcomes: Through case studies and clinical trials, the congress will assess the tangible impact of MRI-guided radiotherapy on patient outcomes, including survival rates, treatment toxicity, and quality of life.

 

• Future Directions and Collaborative Initiatives: The congress will provide a platform for researchers, clinicians, and industry experts to discuss future directions in MRI-guided radiotherapy, fostering collaborations for advancing technology, refining protocols, and ultimately improving the standard of care in cancer radiotherapy.

Attachments